This expansion positions Dupixent as the first targeted therapy for COPD, a significant leap in treating this progressive ...
Further, Regeneron's most important medicine, eczema treatment Dupixent, is still flying high. Worldwide sales of Dupixent in ...
Hosted on MSN13h
Top Analyst Reports for UnitedHealth, Bank of America & SAPDupixent to Remain Sanofi's (SNY) Key Top-Line Driver The Zacks analyst expects Dupixent to remain Sanofi's key top-line driver as it enjoys strong demand trends. Sanofi has also accelerated its ...
A major news story from Sanofi this month is that "The European Medicines Agency has approved Dupixent (dupilumab) to treat ...
As a wave of patent expirations encroaches upon many of the world’s top drugmakers, companies will need to be diligent in ...
On Wednesday, BioNTech SE (NASDAQ:BNTX) agreed to acquire Biotheus, a clinical-stage biotechnology company focused on ...
Citi initiated coverage of Regeneron (REGN) with a Neutral rating and $895 price target Multiple clinical data readouts should “keep ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback